ArticleiScience2026
VPS33B regulates MHC class II antigen presentation in dendritic cells to drive CD4 T cell immunity.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vacuolar protein sorting-associated protein (VPS)33B is essential for endosomal-lysosomal fusion, with its dysfunction linked to arthrogryposis, renal dysfunction, and cholestasis (ARC) syndrome. VPS33B has been implicated in mediating Toll-like receptor degradation in macrophages, a critical step to mitigate inflammation. Here, we uncover a pivotal function of VPS33B in dendritic cell (DC)-mediated antigen presentation. Loss of VPS33B in DCs impairs peptide-MHC class II presentation, leading to diminished CD4 T cell responses. Absence of VPS33B selectively compromises CD4-dependent CD8 T cell responses while not impacting CD4-independent CD8 T cell priming, indicating that VPS33B only affects the MHC class II pathway. Mechanistically, we find that VPS33B is required for optimal presentation of MHC class II-associated peptides as VPS33B-deficient DCs predominantly express MHC class II loaded with invariant chain degradation intermediates. Our work highlights VPS33B as a key regulator of antigen presentation and underscores its importance in orchestrating CD4 T cell-mediated immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.